StockUK listing UK0QIULSEDefensive Anchor

Novo Nordisk A/S Class B(0QIU) Stock Analysis

DKK --+0.00%
Reward58Moderate
Risk13Low
75%Data
Strong 33% profit margin · Revenue growing 32% YoY
DKK —+0.00 (+0.00%) Previous close · LSE
Market cap 19.90Bn
Reward Rating58 Moderate reward assessment · 75% data coverage
Top 50% of stocksView factors
Risk Rating13 Low risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on 0QIU to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Novo Nordisk A/S Class B?

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide.

AI Brief Pro

The brief on Novo Nordisk A/S Class B

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Novo Nordisk A/S Class B?

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The company is listed on the LSE in UK, with a market capitalisation of 19.90B, and a P/E ratio of 0.4x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (58)
Company Information
SectorN/A
IndustryN/A
P/E Ratio0.3896
Beta0.2421
Insider Activity
12M windowAwaiting coverage
LSE director-dealings coverage launching later this year. The data feed is in development.